Halozyme Therapeutics (NASDAQ:HALO) COO Cortney Caudill Sells 8,857 Shares

Key Points

• COO Cortney Caudill sold a total of 28,857 shares over March 9–10 for about $1.96 million (20,000 shares at $67.80 on Mar 9 and 8,857 at $67.64 on Mar 10), reducing her direct stake to 7,055 shares (a 55.66% decrease).
• Halozyme missed quarterly EPS, reporting ($0.24) versus analysts' $1.92 consensus (a $2.16 miss), while revenue of $451.77 million beat estimates and rose 51.6% year‑over‑year.
• Analyst views are mixed (six Buy, five Hold, one Sell) with an average target of $78.56, and institutional investors hold 97.79% of the company’s stock.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) COO Cortney Caudill sold 8,857 shares of the business's stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total transaction of $599,087.48. Following the sale, the chief operating officer directly owned 7,055 shares in the company, valued at $477,200.20. The trade was a 55.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Cortney Caudill also recently made the following trade(s):

• On Monday, March 9th, Cortney Caudill sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $67.80, for a total value of $1,356,000.00.

Halozyme Therapeutics Stock Down 0.5%

Shares of NASDAQ HALO traded down $0.33 during trading on Tuesday, reaching $67.81. The company had a trading volume of 1,353,725 shares, compared to its average volume of 1,907,861. Halozyme Therapeutics, Inc. has a 12-month low of $47.50 and a 12-month high of $82.22. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. The business's 50-day moving average is $72.64 and its 200 day moving average is $70.67. The stock has a market cap of $8.00 billion, a PE ratio of 18.03, a P/E/G ratio of 0.28 and a beta of 0.98.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The firm had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. During the same quarter in the prior year, the business posted $1.26 earnings per share. The firm's revenue for the quarter was up 51.6% compared to the same quarter last year. As a group, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

HALO has been the topic of a number of research analyst reports. TD Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. The Goldman Sachs Group reiterated a "sell" rating and issued a $56.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, December 4th. Benchmark lifted their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, February 19th. Weiss Ratings lowered shares of Halozyme Therapeutics from a "buy (b-)" rating to a "hold (c)" rating in a report on Tuesday, February 24th. Finally, HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $78.56.

Institutional Investors Weigh In On Halozyme Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC grew its stake in shares of Halozyme Therapeutics by 2,136.0% in the 3rd quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company's stock worth $1,751,000 after buying an additional 22,813 shares in the last quarter. Arbor Investment Advisors LLC bought a new stake in Halozyme Therapeutics in the third quarter worth $1,316,000. Monument Capital Management bought a new position in Halozyme Therapeutics during the third quarter valued at $2,015,000. Pacer Advisors Inc. boosted its stake in shares of Halozyme Therapeutics by 2,054.7% during the 3rd quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company's stock worth $35,121,000 after purchasing an additional 456,649 shares during the period. Finally, Cardinal Capital Management purchased a new stake in Halozyme Therapeutics in the 3rd quarter worth about $1,303,000. Institutional investors own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.